Clinical study

This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...

Many people with Crohn’s and IBD turn to Instagram Reels for information. This study found that a lot of that content is only moderate in quality and some contains clinically significant misinformation, which could...

Many people with Crohn’s look to short social videos for information. Moderate-quality and misleading reels could influence treatment decisions, emotional wellbeing, and when people seek medical care.

People with Crohn’s disease often seek information and support on social media; this study shows Instagram Reels vary in quality and medical-advice videos may include misinformation. That matters because inaccurate...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

A reliable, accurate intestinal ultrasound could make routine monitoring easier, faster, and less costly than repeated MRI for people with Crohn’s disease. The study shows strong agreement between ultrasound scores and...

This study links an HLA gene (DRB1) to shared T cell receptor patterns in both Crohn’s disease and ulcerative colitis, suggesting common immune targets across IBD subtypes. That could help researchers identify antigens...

The atlas maps which genes and cell types are different in Crohn's disease, offering clues about why inflammation persists and pointing to specific immune pathways (like JAK/STAT) that are already drug targets. The...

This study maps gene activity in over a million gut cells and finds lasting molecular changes in stem cells after inflammation, which could help explain recurrence and guide future research toward new drug targets.

This study suggests that regional differences in how often and how early advanced drugs are used didn’t change 10-year rates of surgery, hospitalization, or progression to complicated Crohn’s disease in this cohort.

Long-term (five-year) data suggest guselkumab may provide sustained clinical and endoscopic benefit for people with moderate-to-severe Crohn’s disease, which is important for disease control and reducing need for...

This describes an investigational drug approach (PALI-2108) aimed at intestinal fibrosis, a key issue in fibrostenotic Crohn’s disease for which there are no approved antifibrotic therapies. Patients and clinicians may...

This reports preclinical Crohn’s disease research linking creeping fat to intestinal scarring and the creation of a mouse model to study fibrosis and test interventions — an early step toward therapies for strictures.

New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...

The study identifies colonic gene-expression programs that correlate with treatment failure, higher surgery rates, and perianal disease in Crohn’s — findings that could guide future prognostic tests and targeted...

New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.

If you had bowel surgery for Crohn’s disease and develop postoperative anastomotic bleeding, this study suggests endoscopic treatment can stop bleeding in most patients and may avoid another operation. Patients who need...

Surgical technique after ileocolic resection may influence how likely Crohn’s disease is to come back near the anastomosis.

This study suggests a different treatment target for Crohn’s disease: fixing damaged intestinal lining rather than only suppressing inflammation. If validated in humans, repurposed cancer drugs could speed development of...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

How “moderate” IBD is defined affects who is enrolled in trials, who is offered advanced therapies, and how clinicians make treatment decisions. Inconsistent definitions could delay appropriate care for people who might...

This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.

The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. The original article is from msn.com.

Treg cell therapy aims to reduce harmful immune activity that drives Crohn's disease. If developed successfully, it could become a targeted cell-based treatment option for patients who don't respond to current therapies.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from pressreader.com.

This research suggests genetic risk scores could help identify people with IBD who are more likely to have severe disease, which might eventually inform earlier monitoring or treatment decisions. It’s a step toward more...

The study suggests a blood cytokine (CXCL9) could help noninvasively detect intestinal inflammation in Crohn’s disease, which might one day reduce reliance on colonoscopy for monitoring disease activity.

The study suggests that clinical remission on biologics can hide ongoing gut microbiome, metabolite, and epithelial abnormalities that may influence flare risk. This matters because focusing only on immune suppression...

Perianal abscesses or fistulas in children can be an early sign of Crohn's disease. Recognizing which kids are at higher risk helps guide follow-up and testing so diagnosis isn't delayed.

IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.

This study suggests using both faecal calprotectin and intestinal ultrasound together can better identify patients who reach deeper, transmural healing — and those patients had lower risk of bowel-damage progression....

Genetic ancestry can influence IBD risk and disease course, and most prior studies focused on European populations.

Fatigue is a common, often persistent symptom in Crohn’s disease even during remission. This study suggests brain structure differences may be linked to fatigue when inflammation is low, pointing to potential...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from degruyterbrill.com.

Environmental pollutants are increasingly linked to Crohn's disease risk, especially when exposures occur in early life. Understanding these links may help explain rising IBD rates and guide future prevention research.

Earlier detection of small-bowel Crohn’s disease with capsule endoscopy could help guide earlier or more targeted treatment and may lower flare rates, which matters to people trying to avoid disease progression and...

Distinguishing Crohn’s from ulcerative colitis can be hard and often requires invasive tests. A reliable blood test would speed diagnosis and help patients start the right treatments sooner. This study is an early step...

Fatigue is a common, burdensome symptom in Crohn's disease and hard to treat. This study links fatigue severity to differences in brain resting-state connectivity, suggesting brain–gut interactions may play a role.

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Upadacitinib. Open the original article for the...

This study suggests viral exposures—specifically Epstein–Barr virus—might be associated with later development of Crohn’s disease, which could help researchers study disease triggers. If confirmed, such findings might...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for...

This study provides real‑world data on upadacitinib’s ability to produce clinical and endoscopic remission in people with Crohn’s disease, information that can help patients and clinicians weigh treatment options.

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from msn.com.

This study offers a noninflammatory explanation for why many people with Crohn’s continue to have symptoms despite controlled inflammation: sulfur-producing gut microbes and their hydrogen sulfide byproduct. That could...

This study suggests intestinal ultrasound findings early after diagnosis — especially achieving “transmural remission” within 3 months — may predict better 1-year outcomes (sustained steroid-free remission and less need...

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. Open the original article...

Based on the title and source metadata, this appears to be a clinical study related to Irritable bowel syndrome, Upadacitinib, and JAK inhibitor. The original article is from msn.com.